CN103550517B - 一种治疗肝癌的药物 - Google Patents
一种治疗肝癌的药物 Download PDFInfo
- Publication number
- CN103550517B CN103550517B CN201310531322.4A CN201310531322A CN103550517B CN 103550517 B CN103550517 B CN 103550517B CN 201310531322 A CN201310531322 A CN 201310531322A CN 103550517 B CN103550517 B CN 103550517B
- Authority
- CN
- China
- Prior art keywords
- radix
- herba
- fructus
- blood
- heat
- Prior art date
Links
- 239000003814 drugs Substances 0.000 title claims abstract description 22
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 13
- 206010073071 Hepatocellular carcinoma Diseases 0.000 title claims abstract description 12
- 241000208340 Araliaceae Species 0.000 claims abstract description 5
- 241000255791 Bombyx Species 0.000 claims abstract description 5
- 241000756943 Codonopsis Species 0.000 claims abstract description 5
- 241000222336 Ganoderma Species 0.000 claims abstract description 5
- 239000009636 Huang Qi Substances 0.000 claims abstract description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 5
- 210000002826 Placenta Anatomy 0.000 claims abstract description 5
- 241001250596 Pleione Species 0.000 claims abstract description 5
- 241000222640 Polyporus Species 0.000 claims abstract description 5
- 239000010135 fructus aurantii immaturus Substances 0.000 claims abstract description 5
- 239000009969 fructus bruceae Substances 0.000 claims abstract description 5
- 235000005035 ginseng Nutrition 0.000 claims abstract description 5
- 235000008434 ginseng Nutrition 0.000 claims abstract description 5
- 239000011901 water Substances 0.000 claims description 6
- 229940079593 drugs Drugs 0.000 claims description 4
- 210000004369 Blood Anatomy 0.000 abstract description 32
- 239000008280 blood Substances 0.000 abstract description 32
- 210000003734 Kidney Anatomy 0.000 abstract description 19
- 231100000614 Poisons Toxicity 0.000 abstract description 18
- 230000001737 promoting Effects 0.000 abstract description 14
- 239000003440 toxic substances Substances 0.000 abstract description 13
- 230000017531 blood circulation Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 201000010099 diseases Diseases 0.000 abstract description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 5
- 239000002994 raw materials Substances 0.000 abstract 1
- 210000004185 Liver Anatomy 0.000 description 30
- 235000009508 confectionery Nutrition 0.000 description 19
- 208000002193 Pain Diseases 0.000 description 17
- 230000036407 pain Effects 0.000 description 17
- 210000004072 Lung Anatomy 0.000 description 14
- 206010007247 Carbuncle Diseases 0.000 description 11
- 210000000952 Spleen Anatomy 0.000 description 11
- 230000035922 thirst Effects 0.000 description 9
- 206010037660 Pyrexia Diseases 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 7
- 208000004880 Polyuria Diseases 0.000 description 7
- 230000035619 diuresis Effects 0.000 description 7
- 230000002440 hepatic Effects 0.000 description 7
- 230000025627 positive regulation of urine volume Effects 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 6
- 208000001848 Dysentery Diseases 0.000 description 6
- 210000000232 Gallbladder Anatomy 0.000 description 6
- 206010023126 Jaundice Diseases 0.000 description 6
- 208000008425 Protein Deficiency Diseases 0.000 description 6
- 206010042674 Swelling Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000002522 swelling Effects 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 208000002173 Dizziness Diseases 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 206010022114 Injuries Diseases 0.000 description 5
- 206010040872 Skin infection Diseases 0.000 description 5
- 210000002784 Stomach Anatomy 0.000 description 5
- 230000036528 appetite Effects 0.000 description 5
- 235000019789 appetite Nutrition 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- 206010003549 Asthenia Diseases 0.000 description 4
- 210000001124 Body Fluids Anatomy 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 description 4
- 206010017553 Furuncle Diseases 0.000 description 4
- 210000002216 Heart Anatomy 0.000 description 4
- 210000001624 Hip Anatomy 0.000 description 4
- 210000000214 Mouth Anatomy 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 4
- 210000004915 Pus Anatomy 0.000 description 4
- 201000000736 amenorrhea Diseases 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000000686 essences Substances 0.000 description 4
- 230000001939 inductive effects Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 206010000077 Abdominal mass Diseases 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 206010010726 Conjunctival oedema Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 208000005679 Eczema Diseases 0.000 description 3
- 208000001780 Epistaxis Diseases 0.000 description 3
- 210000003026 Hypopharynx Anatomy 0.000 description 3
- 206010022437 Insomnia Diseases 0.000 description 3
- 210000003127 Knee Anatomy 0.000 description 3
- 206010027327 Menstrual diseases Diseases 0.000 description 3
- 208000009205 Tinnitus Diseases 0.000 description 3
- 231100000611 Venom Toxicity 0.000 description 3
- 210000001048 Venoms Anatomy 0.000 description 3
- 230000003187 abdominal Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 201000004624 dermatitis Diseases 0.000 description 3
- 231100001003 eczema Toxicity 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 230000000968 intestinal Effects 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 230000001717 pathogenic Effects 0.000 description 3
- 239000002574 poisons Substances 0.000 description 3
- 230000001047 pyretic Effects 0.000 description 3
- 230000000268 renotropic Effects 0.000 description 3
- 230000002269 spontaneous Effects 0.000 description 3
- 231100000886 tinnitus Toxicity 0.000 description 3
- 239000002435 venoms Substances 0.000 description 3
- 230000002087 whitening Effects 0.000 description 3
- 210000001015 Abdomen Anatomy 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 241000668709 Dipterocarpus costatus Species 0.000 description 2
- 206010013990 Dysuria Diseases 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 206010018498 Goitre Diseases 0.000 description 2
- 206010018830 Haematemesis Diseases 0.000 description 2
- 208000002672 Hepatitis B Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 210000003205 Muscles Anatomy 0.000 description 2
- 206010029410 Night sweats Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 210000003516 Pericardium Anatomy 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010037844 Rash Diseases 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 206010067868 Skin mass Diseases 0.000 description 2
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 2
- 210000003932 Urinary Bladder Anatomy 0.000 description 2
- 206010052769 Vertigos Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000003203 everyday Effects 0.000 description 2
- 230000003419 expectorant Effects 0.000 description 2
- 239000003172 expectorant agents Substances 0.000 description 2
- 230000002349 favourable Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 230000000414 obstructive Effects 0.000 description 2
- 244000052769 pathogens Species 0.000 description 2
- 238000002360 preparation methods Methods 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 238000007086 side reactions Methods 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 239000003053 toxins Substances 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010002383 Angina pectoris Diseases 0.000 description 1
- 208000002399 Aphthous Stomatitis Diseases 0.000 description 1
- 210000001367 Arteries Anatomy 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 206010007554 Cardiac failure Diseases 0.000 description 1
- 206010007625 Cardiogenic shock Diseases 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 241001517488 Clavus Species 0.000 description 1
- 206010061428 Decreased appetite Diseases 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- 206010016256 Fatigue Diseases 0.000 description 1
- 240000000773 Garcinia xanthochymus Species 0.000 description 1
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 208000001786 Gonorrhea Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010018836 Haematochezia Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000006750 Hematuria Diseases 0.000 description 1
- 208000002287 Hemorrhoids Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- 210000000867 Larynx Anatomy 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000004396 Mastitis Diseases 0.000 description 1
- 206010028334 Muscle spasms Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000218979 Populus sp. Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010072736 Rheumatic diseases Diseases 0.000 description 1
- 244000171263 Ribes grossularia Species 0.000 description 1
- 208000005687 Scabies Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 210000000582 Semen Anatomy 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010042170 Strangury Diseases 0.000 description 1
- 206010042576 Suppressed lactation Diseases 0.000 description 1
- 210000002435 Tendons Anatomy 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 206010044008 Tonsillitis Diseases 0.000 description 1
- 231100000765 Toxins Toxicity 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 206010050040 VIIth nerve paralysis Diseases 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000009257 Visceral Prolapse Diseases 0.000 description 1
- 206010063840 Visceroptosis Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical methods Methods 0.000 description 1
- 230000000118 anti-eoplastic Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 239000003146 anticoagulant agents Substances 0.000 description 1
- 230000001914 calming Effects 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound data:image/svg+xml;base64,<?xml version='1.0' encoding='iso-8859-1'?>
<svg version='1.1' baseProfile='full'
              xmlns='http://www.w3.org/2000/svg'
                      xmlns:rdkit='http://www.rdkit.org/xml'
                      xmlns:xlink='http://www.w3.org/1999/xlink'
                  xml:space='preserve'
width='300px' height='300px' viewBox='0 0 300 300'>
<!-- END OF HEADER -->
<rect style='opacity:1.0;fill:#FFFFFF;stroke:none' width='300' height='300' x='0' y='0'> </rect>
<path class='bond-0' d='M 109.617,162.917 L 123.844,161.067 L 122.833,157.334 Z' style='fill:#3B4143;fill-rule:evenodd;fill-opacity=1;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-0' d='M 123.844,161.067 L 136.049,151.751 L 138.071,159.218 Z' style='fill:#E84235;fill-rule:evenodd;fill-opacity=1;stroke:#E84235;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-0' d='M 123.844,161.067 L 122.833,157.334 L 136.049,151.751 Z' style='fill:#E84235;fill-rule:evenodd;fill-opacity=1;stroke:#E84235;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-13' d='M 156.836,162.642 L 165.603,171.361' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-13' d='M 165.603,171.361 L 174.369,180.081' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1' d='M 109.617,162.917 L 99.7067,200.302' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-21' d='M 109.617,162.917 L 82.195,135.642' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-2' d='M 99.7067,200.302 L 62.3753,210.412' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-3' d='M 62.3753,210.412 L 23.7468,208.492' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-23' d='M 62.3753,210.412 L 67.2933,197.497' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-23' d='M 67.2933,197.497 L 72.2113,184.582' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-24' d='M 62.3753,210.412 L 73.5517,234.594 L 80.0277,230.364 Z' style='fill:#3B4143;fill-rule:evenodd;fill-opacity=1;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-4' d='M 23.7468,208.492 L 13.6364,171.161' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-5' d='M 13.6364,171.161 L 46.0163,150.009' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6' d='M 46.0163,150.009 L 56.3501,158.331' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6' d='M 56.3501,158.331 L 66.6839,166.654' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-8' d='M 46.0163,150.009 L 82.195,135.642' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-25' d='M 46.0163,150.009 L 51.2869,121.886 L 43.5612,121.502 Z' style='fill:#3B4143;fill-rule:evenodd;fill-opacity=1;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-7' d='M 85.5934,168.993 L 89.8409,166.624' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7' d='M 89.8409,166.624 L 94.0884,164.254' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-9' d='M 82.195,135.642 L 95.8433,99.248 L 88.3663,97.2661 Z' style='fill:#3B4143;fill-rule:evenodd;fill-opacity=1;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-10' d='M 94.8323,95.5149 L 86.0656,86.7951' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10' d='M 86.0656,86.7951 L 77.2988,78.0753' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10' d='M 89.3773,100.999 L 80.6106,92.2794' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10' d='M 80.6106,92.2794 L 71.8439,83.5596' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11' d='M 92.1048,98.2571 L 105.826,94.5408' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11' d='M 105.826,94.5408 L 119.548,90.8246' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-12' d='M 132.17,77.833 L 135.758,64.2973' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-12' d='M 135.758,64.2973 L 139.346,50.7615' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 170.631,179.09 L 167.043,192.626' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 167.043,192.626 L 163.455,206.162' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 178.108,181.072 L 174.52,194.608' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 174.52,194.608 L 170.932,208.144' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-15' d='M 174.369,180.081 L 211.701,169.971' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-16' d='M 211.701,169.971 L 239.122,197.246' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-16' d='M 221.269,168.578 L 240.464,187.67' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-22' d='M 211.701,169.971 L 221.611,132.586' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-17' d='M 239.122,197.246 L 276.454,187.135' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-18' d='M 276.454,187.135 L 286.364,149.75' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-18' d='M 270.463,179.545 L 277.4,153.376' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-19' d='M 286.364,149.75 L 258.942,122.475' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-20' d='M 258.942,122.475 L 221.611,132.586' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-20' d='M 255.364,131.458 L 229.232,138.535' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<text dominant-baseline="central" text-anchor="middle" x='146.948' y='154.74' style='font-size:12px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#E84235' ><tspan>O</tspan></text>
<text dominant-baseline="central" text-anchor="start" x='71.8408' y='176.202' style='font-size:12px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>N</tspan></text>
<text dominant-baseline="central" text-anchor="end" x='69.4145' y='72.9161' style='font-size:12px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#E84235' ><tspan>O</tspan></text>
<text dominant-baseline="central" text-anchor="start" x='124.705' y='90.0805' style='font-size:12px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#E84235' ><tspan>O</tspan></text>
<text dominant-baseline="central" text-anchor="start" x='159.728' y='219.4' style='font-size:12px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#E84235' ><tspan>O</tspan></text>
<text dominant-baseline="central" text-anchor="start" x='79.229' y='244.726' style='font-size:12px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#3B4143' ><tspan>H</tspan></text>
<text dominant-baseline="central" text-anchor="start" x='43.639' y='113.314' style='font-size:12px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#3B4143' ><tspan>H</tspan></text>
</svg>
 data:image/svg+xml;base64,<?xml version='1.0' encoding='iso-8859-1'?>
<svg version='1.1' baseProfile='full'
              xmlns='http://www.w3.org/2000/svg'
                      xmlns:rdkit='http://www.rdkit.org/xml'
                      xmlns:xlink='http://www.w3.org/1999/xlink'
                  xml:space='preserve'
width='85px' height='85px' viewBox='0 0 85 85'>
<!-- END OF HEADER -->
<rect style='opacity:1.0;fill:#FFFFFF;stroke:none' width='85' height='85' x='0' y='0'> </rect>
<path class='bond-0' d='M 30.558,45.6598 L 35.137,44.9873 L 34.8505,43.9296 Z' style='fill:#3B4143;fill-rule:evenodd;fill-opacity=1;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-0' d='M 35.137,44.9873 L 39.143,42.1994 L 39.7159,44.3149 Z' style='fill:#E84235;fill-rule:evenodd;fill-opacity=1;stroke:#E84235;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-0' d='M 35.137,44.9873 L 34.8505,43.9296 L 39.143,42.1994 Z' style='fill:#E84235;fill-rule:evenodd;fill-opacity=1;stroke:#E84235;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-13' d='M 42.841,44.4918 L 45.8729,47.5074' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-13' d='M 45.8729,47.5074 L 48.9047,50.523' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1' d='M 30.558,45.6598 L 27.7502,56.2522' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-21' d='M 30.558,45.6598 L 22.7886,37.932' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-2' d='M 27.7502,56.2522 L 17.173,59.1169' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-3' d='M 17.173,59.1169 L 6.22825,58.5727' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-23' d='M 17.173,59.1169 L 18.7751,54.9096' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-23' d='M 18.7751,54.9096 L 20.3772,50.7023' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-24' d='M 17.173,59.1169 L 21.0555,67.0641 L 22.8903,65.8655 Z' style='fill:#3B4143;fill-rule:evenodd;fill-opacity=1;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-4' d='M 6.22825,58.5727 L 3.36364,47.9955' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-5' d='M 3.36364,47.9955 L 12.538,42.0025' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6' d='M 12.538,42.0025 L 16.0138,44.8018' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6' d='M 16.0138,44.8018 L 19.4896,47.6011' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-8' d='M 12.538,42.0025 L 22.7886,37.932' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-25' d='M 12.538,42.0025 L 14.0858,32.9386 L 11.8968,32.8298 Z' style='fill:#3B4143;fill-rule:evenodd;fill-opacity=1;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-7' d='M 22.6556,47.9928 L 24.407,47.0157' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7' d='M 24.407,47.0157 L 26.1584,46.0386' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-9' d='M 22.7886,37.932 L 26.6556,27.6203 L 24.5371,27.0587 Z' style='fill:#3B4143;fill-rule:evenodd;fill-opacity=1;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-10' d='M 26.3692,26.5626 L 23.3373,23.547' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10' d='M 23.3373,23.547 L 20.3055,20.5314' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10' d='M 24.8236,28.1164 L 21.7918,25.1009' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10' d='M 21.7918,25.1009 L 18.7599,22.0853' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11' d='M 25.5964,27.3395 L 30.0321,26.1382' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11' d='M 30.0321,26.1382 L 34.4678,24.9369' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-12' d='M 36.6577,22.6485 L 37.8196,18.2655' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-12' d='M 37.8196,18.2655 L 38.9814,13.8824' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 47.8454,50.2422 L 46.6836,54.6253' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 46.6836,54.6253 L 45.5218,59.0083' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 49.9639,50.8038 L 48.8021,55.1868' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 48.8021,55.1868 L 47.6403,59.5699' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-15' d='M 48.9047,50.523 L 59.4819,47.6584' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-16' d='M 59.4819,47.6584 L 67.2513,55.3863' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-16' d='M 62.1929,47.2637 L 67.6315,52.6732' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-22' d='M 59.4819,47.6584 L 62.2897,37.066' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-17' d='M 67.2513,55.3863 L 77.8286,52.5216' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-18' d='M 77.8286,52.5216 L 80.6364,41.9292' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-18' d='M 76.1313,50.3712 L 78.0967,42.9565' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-19' d='M 80.6364,41.9292 L 72.8669,34.2014' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-20' d='M 72.8669,34.2014 L 62.2897,37.066' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-20' d='M 71.8533,36.7465 L 64.4492,38.7517' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<text dominant-baseline="central" text-anchor="middle" x='41.1352' y='43.3431' style='font-size:3px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#E84235' ><tspan>O</tspan></text>
<text dominant-baseline="central" text-anchor="start" x='19.8549' y='49.4238' style='font-size:3px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>N</tspan></text>
<text dominant-baseline="central" text-anchor="end" x='19.1674' y='20.1596' style='font-size:3px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#E84235' ><tspan>O</tspan></text>
<text dominant-baseline="central" text-anchor="start" x='34.8331' y='25.0228' style='font-size:3px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#E84235' ><tspan>O</tspan></text>
<text dominant-baseline="central" text-anchor="start" x='44.7564' y='61.6634' style='font-size:3px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#E84235' ><tspan>O</tspan></text>
<text dominant-baseline="central" text-anchor="start" x='21.9482' y='68.8391' style='font-size:3px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#3B4143' ><tspan>H</tspan></text>
<text dominant-baseline="central" text-anchor="start" x='11.8644' y='31.6057' style='font-size:3px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#3B4143' ><tspan>H</tspan></text>
</svg>
 O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000000994 depressed Effects 0.000 description 1
- 230000000916 dilatatory Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering processes Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019525 fullness Nutrition 0.000 description 1
- 239000007789 gases Substances 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002607 hemopoietic Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001976 improved Effects 0.000 description 1
- 230000004054 inflammatory processes Effects 0.000 description 1
- 239000004615 ingredients Substances 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007788 liquids Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 201000004044 liver cirrhosis Diseases 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 201000005505 measles Diseases 0.000 description 1
- 230000002175 menstrual Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 201000008125 pain agnosia Diseases 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000552 rheumatic Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000003393 splenic Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001502 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000224 toxic side effects Toxicity 0.000 description 1
- 231100000397 ulcers Toxicity 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Abstract
本发明公开了一种治疗肝癌的药物。它由下述原料药制成：人参、熟地黄、党参、灵芝、鳖甲、夏枯草、白花蛇舌草、鱼腥草、鸦胆子、蒲黄、半枝莲、黄芪、山豆根、柴胡、丹参、枸杞子、女贞子、墨旱莲、五味子、当归、巴戟天、益母草、茵陈、猪苓、玉竹、赤芍、牡丹皮、山慈菇、僵蚕、鸡血藤、枳实、田基黄、紫草、垂盆草、紫河车和甘草。本发明以上述药物组方，具有舒肝解郁、补肾养阴，消癥散、清热解毒、活血化瘀、化痰利湿、软坚散结、补气养血和滋阴培元的功效，从而有效的治疗肝癌，并可以治愈部分早期肝癌。
Description
技术领域
[0001] 本发明涉及一种治疗肝癌的药物，属于中药技术领域。
背景技术
[0002] 肝癌是临床上最常见的恶性肿瘤之一，根据最新统计，全世界每年新发肝癌患者约六十万，居恶性肿瘤的第五位。肝癌在我国属于高发病，一般男性多于女性。中国是乙肝大国，我国的肝癌多在乙肝肝硬化的基础上发展而来，丙肝病人也在逐渐增加，乙肝后也会发展为肝癌。目前我国发病人数约占全球的半数以上，占全球肝癌病人的55%，已经成为严重威胁我国人民健康和生命的一大杀手，其危险性不容小视。而做好肝癌的早期诊断及治疗对于治疗肝癌非常重要。
[0003] 传统的治疗肝癌的方法是手术切除及放化疗，上述方式对人体的伤害极大。
发明内容
[0004] 本发明克服了上述现有技术的不足，提供了一种治疗肝癌的药物，该药物采用纯然的中药材，对人体基本没有危害，不仅可以有效治疗肝癌，还可以增强患者抵抗力。
[0005] 本发明的技术方案是:一种治疗肝癌的药物，其特征是，由下述重量的原料药制成:人参10g、熟地黄15g、党参10g、灵芝8g、鳖甲15g、夏枯草10g、白花蛇舌草10g、鱼腥草10g、鸦胆子10g、蒲黄10g、半枝莲10g、黄苗10g、山豆根8g、柴胡15g、丹参12g、枸紀子10g、女贞子10g、墨旱莲10g、五味子10g、当归10g、巴戟天8g、益母草10g、茵陈10g、猪苳8g、玉竹10g、赤芍8g、牡丹皮7g、山慈菇10g、僵蚕15g、鸡血藤15g、枳实8g、田基黄10g、紫草10g、垂盆草8g、紫河车8g和甘草5g。
[0006] 制备及服用方法:水煎煮，分两次早晚服用。I个月为I个疗程。
[0007] 各中药的药理作用:
[0008] 人参:甘、微苦，平。归脾、肺、心经。功能与主治:大补元气，复脉固脱，补脾益肺，生津，安神。用于体虚欲脱，肢冷脉微，脾虚食少，肺虚喘咳，津伤口渴，内热消渴，久病虚羸，惊悸失眠，阳瘘宫冷；心力衰竭，心原性休克。
[0009] 熟地黄:甘，微温。归肝、肾经。功能与主治:补血滋阴，益精填髓。用于血虚萎黄，心悸怔忡，月经不调，崩漏下血，肝肾阴虚，腰膝酸软，骨蒸潮热，盗汗遗精，内热消渴，眩晕，耳鸣，须发早白。
[0010] 党参:甘，平。归脾、肺经。健脾益肺，养血生津。用于脾肺气虚，食少倦怠，咳嗽虚喘，气血不足，面色萎黄，心悸气短，津伤口渴，内热消渴。
[0011] 灵芝:甘，平。归心、肺、肝、肾经。具有抗肿瘤及保肝解毒的作用。
[0012] 鳖甲:咸，微寒。归肝、肾经。滋阴潜阳，退热除蒸，软坚散结。用于阴虚发热，骨蒸劳热，阴虚阳尤，头晕目眩，虚风内动。
[0013] 夏枯草:辛、苦，寒。归肝、胆经。功能与主治:清火，明目，散结，消肿。用于目赤肿痛，目珠夜痛，头痛眩晕，瘰疬，瘿瘤，乳痈肿痛；甲状腺肿大，淋巴结结核，乳腺增生，高血压。
[0014] 白花蛇舌草:苦甘，寒。无毒，入心经、肝经、脾经。功效:清热解毒；利湿。主治:肺热喘咳；咽喉肿痛；肠痈；疖肿疮疡；毒蛇咬伤；热淋涩痛；水肿；痢疾；肠炎；湿热黄疸；擅长治疗多种癌症。
[0015] 鱼腥草:清热解毒；排脓消痈；利尿通淋。主治:热淋主肺痈吐脓；痰热喘咳；喉哦；热痢；痈肿疮毒。功效:清热解毒，利尿消肿。治肺炎，疟疾，水肿，淋病，白带，痈肿，痔疮，脱肛，湿瘆，秃疮，疥癣等。
[0016] 鸦胆子:苦，寒；有小毒。归大肠、肝经。功能与主治:清热解毒，截疟，止痢，腐蚀赘疣。用于痢疾，疟疾；外治赘疣，鸡眼。
[0017] 蒲黄:甘，平。归肝、心包经。功能与主治:止血，化瘀，通淋。用于吐血，衄血，咯血，崩漏，外伤出血，经闭痛经，脘腹刺痛，跌扑肿痛，血淋涩痛。
[0018] 半枝莲:辛、苦，寒。归肺、肝、肾经。功能与主治:清热解毒，化瘀利尿。用于疔疮肿毒，咽喉肿痛，毒蛇咬伤，跌扑伤痛，水肿，黄疸
[0019] 黄芪:甘，温。归肺、脾经。功能与主治:补气固表，利尿托毒，排脓，敛疮生肌。用于气虚乏力，食少便溏，中气下陷，久泻脱肛，便血崩漏，表虚自汗，气虚水肿，痈疽难溃，久溃不敛，血虚瘘黄，内热消渴；慢性肾炎蛋白尿，糖尿病。
[0020] 山豆根:苦，寒；有毒。归肺、胃经。清热解毒，消肿利咽。用于火毒蕴结症。
[0021] 柴胡:性微寒，味苦、辛；归肝经、胆经，具疏肝利胆、疏气解郁、散火之功效。
[0022] 丹参:苦，微寒。归心、肝经。功能与主治:活血祛瘀，通经止痛，清心除烦，凉血消痈。用于胸痹心痛，脘腹胁痛，瘕瘕积聚，热痹疼痛，心烦不眠，月经不调，痛经经闭，疮疡肿痛。
[0023] 枸杞子:甘，平。归肝、肾经。滋补肝肾，益精明目。用于虚劳精亏，腰膝酸痛，眩晕耳鸣，阳萎遗精，内热消渴，血虚萎黄，目昏不明。
[0024] 女贞子:甘、苦，凉。归肝、肾经。滋补肝肾，明目乌发。用于肝肾阴虚，眩晕耳鸣，腰膝酸软，须发早白，目暗不明，内热消渴，骨蒸潮热。
[0025] 墨旱莲:甘、酸，寒。归肾、肝经。功能与主治:滋补肝肾，凉血止血。用于肝肾阴虚，牙齿松动，须发早白，眩晕耳呜，腰膝酸软，阴虚血热吐血、衄血、尿血，血痢，崩漏下血，外伤出血。
[0026] 五味子:酸、甘，温。肺、心、肾经。收敛固涩，益气生津，补肾宁心。用于久嗽虚喘，梦遗滑精，遗尿尿频，久泻不止，自汗盗汗，津伤□渴，内热消渴，心悸失眠。
[0027] 当归:甘、辛，温。归肝、心、脾经。补血活血，调经止痛，润肠通便。用于血虚萎黄，眩晕心悸，月经不调，经闭痛经，虚寒腹痛，风湿痹痛，跌扑损伤，痈疽疮疡，肠燥便秘。酒当归活血通经。
[0028] 巴戟天:甘、辛，微温。归肾、肝经。补肾阳，强筋骨，祛风湿。
[0029] 益母草:苦、辛，微寒。归肝、心包、膀胱经。活血调经，利尿消肿，清热解毒。
[0030] 茵陈:苦、辛，微寒。归脾、胃、肝、胆经。清利湿热，利胆退黄。用于黄疸尿少，湿温暑湿，湿疮瘙痒。
[0031] 猪苓:甘、淡，平。归肾、膀胱经。功能与主治:利水渗湿。用于小便不利，水肿，泄湾，淋池，带下。
[0032] 玉竹:甘，微寒。归肺、胃经。功能与主治:养阴润燥，生津止渴。用于肺胃阴伤，燥热咳嗽，咽干口渴，内热消渴。
[0033] 赤芍:苦，微寒。归肝经。清热凉血，散瘀止痛。用于热入营血，温毒发斑，吐血衄血，目赤肿痛，肝郁胁痛，经闭痛经，癥瘕腹痛，跌扑损伤，痈肿疮疡等。
[0034] 牡丹皮:味苦、辛，性微寒，归心、肝、肾经。具有清热凉血、活血散瘀之功。现代研宄表明，牡丹皮有抗炎、镇痛、止血、保肝的作用。
[0035] 山慈菇:甘，微辛，寒。入肝、脾经。消肿，散结，化痰，解毒。治痈疽疔肿，瘰疬，喉痹肿痛，蛇、虫、狂犬伤。
[0036] 僵蚕:祛风定惊，化痰散结。用于惊风抽搐，咽喉肿痛，颁下淋巴结炎，面神经麻痹，皮肤瘙痒。
[0037] 鸡血藤:味苦、微甘，性温，归肝经。具有行血补血、舒筋活络之功。现代研宄表明，鸡血藤有改善造血系统、扩张血管、增加组织血流量、调节免疫、抗血栓、抗肿瘤的作用。
[0038] 枳实:苦、辛、酸，微寒。归脾、胃经。功能与主治:破气消积，化痰散痞。用于积滞内停，痞满胀痛，泻痢后重，大便不通，痰滞气阻，胸痹，结胸，脏器下垂。
[0039]田基黄:为藤黄科植物地耳草的全草。甘；苦；凉。归肺；肝；胃经。具有清热利湿；解毒；散瘀消肿的功能。主湿热黄疸；泄泻；痢疾；肠痈；痈疖肿毒；乳蛾；口疮；目赤肿痛；毒蛇咬伤；跌打损伤。
[0040] 紫草:甘、咸，寒。归心、肝经。功能与主治:凉血，活血，解毒透瘆。用于血热毒盛，斑瘆紫黑，麻瘆不透，疮疡，湿瘆，水火烫伤。
[0041] 垂盆草:甘、淡，凉。归肝、胆、小肠经。利湿退黄，清热解毒。用于湿热黄疽，小便不利，痈肿疮疡。
[0042] 紫河车:甘、咸，温。归心、肺、肾经。功能与主治:温肾补精，益气养血。用于虚劳羸瘦，骨蒸盗汗，咳嗽气喘，食少气短，阳瘘遗精，不孕少乳。
[0043] 甘草:调和诸药。
[0044] 本发明以上述药物组方，具有舒肝解郁、补肾养阴，消癥散、清热解毒、活血化瘀、化痰利湿、软坚散结、补气养血和滋阴培元的功效，从而有效的治疗肝癌，并可以治愈部分早期肝癌。
[0045] 以下结合临床资料及典型病例对本发明的有益效果进一步说明。
[0046] 一、临床观察
[0047] 1、临床资料:选自2009年6月至2011年9月的门诊及住院患者共154例，其中早期肝癌53例。年龄为42-68岁，平均61.5岁。
[0048] 2、诊断标准:以我国卫生部编的《中国常见恶性肿瘤诊治规范》中的原发性肝癌诊断标准为依据。其中，早期肝癌是指单个癌结节最大直径小于3cm或者两个癌结节合计最大直径小于3cm的原发性肝癌。
[0049] 3、治疗方法:服用本发明药物，水煎煮，分两次早晚服用。I个月为I个疗程。
[0050] 4、疗效评定标准:按照卫生部《中国常见恶性肿瘤诊治规范》中原发性肝癌疗效评定标准，以患者治疗前与治疗后B超或CT进行对照比较，以完全缓解(CR)、部分缓解(PR)、稳定(SD )、进展(PD )进彳丁疗效评定。
[0051 ] 5、治疗结果:完全缓解123例，部分缓解14例，稳定17例，进展O例。有效率(CR +PR)为89%，稳定率(CR + PR + SD)为100%。同时早期53例早期肝癌中有41例治愈(月中瘤全部消失，随访I年未复发)。
[0052] 6、毒副作用分析
[0053] 观察的154例患者中，服用本发明中药后仅有2例出现低热、I例轻度腹泻，出现副反应的几率仅为2.0%，经对症处置副反应消失，其余无任何毒副作用。
[0054] 综上所述，本发明用于治疗肝癌的药物，经临床试验，表明其可有效抑制肝癌发展，改善患者症状、体征，且无明显毒副作用。
[0055] 二、典型病例
[0056] 病例1:杨某，女，62岁，患者症状为腹部闷胀，消化不良，有时恶心、呕吐，不明原因的发热，肝区持续性疼痛，确诊为肝癌，经腹部CT检查发现肿瘤大小为2cmX3cm，经服用本发明药物水煎服，每天一剂，分早晚两次服用。服用I个疗程后，患者腹部闷胀、发热、恶心症状明显减轻，食欲增加，经检查肿瘤缩小为IcmX 2cm，病情好转。继续服用5个月，肝区经检查肿瘤消失。随访I年无复发。
[0057] 病例2:张某，男，58岁。患者肝区胀痛不适、食欲下降、消瘦4个月，B超、CT检查发现肿瘤位于右肝后上部，约7X7cm大小。经服用本发明药物水煎服，每天一剂，分早晚两次服用。服用3个疗程后，患者症状减轻，经检查肿瘤缩小为3cmX4cm，病情好转。继续服用6个月，肝区经检查肿瘤小于I X 2cm。
具体实施方式
[0058] 实施例1
[0059] 配方:人参10g、熟地黄15g、党参10g、灵芝8g、鳖甲15g、夏枯草10g、白花蛇舌草10g、鱼腥草10g、鸦胆子10g、蒲黄10g、半枝莲10g、黄苗10g、山豆根8g、柴胡15g、丹参12g、枸f己子10g、女贞子10g、墨旱莲10g、五味子10g、当归10g、巴戟天8g、益母草10g、茵陈10g、猪苓8g、玉竹10g、赤芍8g、牡丹皮7g、山慈菇10g、僵蚕15g、鸡血藤15g、枳实8g、田基黄10g、紫草10g、垂盆草Sg、紫河车Sg和甘草5g。
[0060] 制备及服用方法:水煎煮，分两次早晚服用。I个月为I个疗程。
Claims (1)
1.一种治疗肝癌的药物，其特征是，由下述重量的原料药制成••人参10g、熟地黄15g、党参10g、灵芝8g、鳖甲15g、夏枯草10g、白花蛇舌草10g、鱼腥草10g、鸦胆子10g、蒲黄10g、半枝莲10g、黄苗10g、山豆根8g、柴胡15g、丹参12g、枸紀子10g、女贞子10g、墨旱莲10g、五味子10g、当归10g、巴戟天8g、益母草10g、茵陈10g、猪苳8g、玉竹10g、赤苟8g、牡丹皮7g、山慈葫10g、僵蚕15g、鸡血藤15g、枳实8g、田基黄10g、紫草10g、垂盆草8g、紫河车8g和甘草5g，水煎煮。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310531322.4A CN103550517B (zh) | 2013-11-01 | 2013-11-01 | 一种治疗肝癌的药物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310531322.4A CN103550517B (zh) | 2013-11-01 | 2013-11-01 | 一种治疗肝癌的药物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103550517A CN103550517A (zh) | 2014-02-05 |
| CN103550517B true CN103550517B (zh) | 2015-07-29 |
Family
ID=50004989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310531322.4A CN103550517B (zh) | 2013-11-01 | 2013-11-01 | 一种治疗肝癌的药物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103550517B (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103977351A (zh) * | 2014-05-23 | 2014-08-13 | 李绍礼 | 一种治疗肝癌的药物组合物 |
| CN104337955A (zh) * | 2014-09-30 | 2015-02-11 | 赵文飞 | 一种治疗肝癌的中药配方及其制备方法 |
| CN104474296A (zh) * | 2014-11-20 | 2015-04-01 | 邹怀亮 | 一种治疗癌症的中药 |
| CN104491737A (zh) * | 2014-12-30 | 2015-04-08 | 潘振奎 | 一种治疗早期肝癌的中药配方 |
| CN105106468A (zh) * | 2015-09-21 | 2015-12-02 | 徐枫 | 一种内科抗肿瘤的中药组合物 |
| CN105582466A (zh) * | 2015-12-31 | 2016-05-18 | 崔鹏 | 一种治疗肝癌早期的中药配方 |
| CN107184822A (zh) * | 2016-03-14 | 2017-09-22 | 陈孝山 | 一种治疗肝癌的中药 |
| CN105797023A (zh) * | 2016-04-11 | 2016-07-27 | 烟台市蓝洋之草医药生物科技有限公司 | 一种中药在制备治疗原发性肝癌的药物中的用途 |
| CN105797024A (zh) * | 2016-04-11 | 2016-07-27 | 烟台市蓝洋之草医药生物科技有限公司 | 一种治疗原发性肝癌的中药 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1408404A (zh) * | 2002-07-22 | 2003-04-09 | 周宝义 | 癌扶平 |
| CN1583141A (zh) * | 2004-06-08 | 2005-02-23 | 唐宗园 | 一种治疗恶性肿瘤的中药 |
| CN101670071A (zh) * | 2009-09-25 | 2010-03-17 | 卢速江 | 治疗癌症的中药制剂及其制备方法 |
| CN101773636A (zh) * | 2009-01-09 | 2010-07-14 | 苏州知微堂生物科技有限公司 | 一种抗肿瘤纳米中药及其生产方法 |
| CN102940773A (zh) * | 2012-12-04 | 2013-02-27 | 邓鑫 | 抑制肝癌转移的中药制剂及其制备方法 |
-
2013
- 2013-11-01 CN CN201310531322.4A patent/CN103550517B/zh not_active IP Right Cessation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1408404A (zh) * | 2002-07-22 | 2003-04-09 | 周宝义 | 癌扶平 |
| CN1583141A (zh) * | 2004-06-08 | 2005-02-23 | 唐宗园 | 一种治疗恶性肿瘤的中药 |
| CN101773636A (zh) * | 2009-01-09 | 2010-07-14 | 苏州知微堂生物科技有限公司 | 一种抗肿瘤纳米中药及其生产方法 |
| CN101670071A (zh) * | 2009-09-25 | 2010-03-17 | 卢速江 | 治疗癌症的中药制剂及其制备方法 |
| CN102940773A (zh) * | 2012-12-04 | 2013-02-27 | 邓鑫 | 抑制肝癌转移的中药制剂及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103550517A (zh) | 2014-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103611094B (zh) | 一种治疗宫颈癌的药物 | |
| CN100584369C (zh) | 一种外用治疗痹症中药组合物 | |
| CN101940766B (zh) | 一种治疗心肌梗塞的药物及其制备方法 | |
| CN104958484A (zh) | 一种活血通络的中药膏及其制备方法 | |
| CN102793822B (zh) | 一种治疗阑尾炎的药物及其制备方法 | |
| CN103705894B (zh) | 一种治疗风湿性关节炎的中药汤剂 | |
| CN103536758B (zh) | 一种治疗阴虚盗汗的中药组合物 | |
| CN100417403C (zh) | 治疗癌症的中药 | |
| CN100586468C (zh) | 一种治疗乙肝的中药 | |
| CN101721664A (zh) | 一种治疗中风偏瘫及全身瘫痪的中药 | |
| CN100558390C (zh) | 一种外用治疗寒湿痹痛的膏剂 | |
| CN103751570B (zh) | 一种内服治疗偏头痛的中药 | |
| CN102552637B (zh) | 治疗肩周炎的中药组合物及其制备方法 | |
| CN101181547B (zh) | 治疗口臭、口干、口苦和口腔溃疡的中药 | |
| CN102166317B (zh) | 一种治疗崩漏的中药组合物 | |
| CN104107318A (zh) | 一种治疗瘀血阻滞型月经不调的中药组合物 | |
| CN102342992B (zh) | 一种用于治疗失眠的中药组合物及其制剂的制备方法 | |
| CN103623358B (zh) | 一种治疗急、慢性咽炎的中药汤剂 | |
| CN101926961B (zh) | 一种内服治疗盆腔炎的中药组合物 | |
| CN103330780B (zh) | 一种治疗下肢静脉曲张的药物及其制备方法 | |
| CN104887889A (zh) | 一种活血生骨的中药丸剂及其制备方法 | |
| CN103463586B (zh) | 一种治疗不安腿综合征的中药组合物 | |
| CN103550695B (zh) | 一种治疗乳腺癌的药物 | |
| CN103417790B (zh) | 治疗脑出血的中药 | |
| CN104474471A (zh) | 一种治疗甲状腺的中药组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Su Lei Inventor before: Tian Jing Inventor before: Zhang Weicong |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150619 Address after: No. 1920 people's Hospital of Zhangqiu City, Zhangqiu City, Ji'nan City, Shandong province 250200 Huiquan Road Applicant after: Su Lei Address before: No. 1920 people's Hospital of Zhangqiu City, Zhangqiu City, Ji'nan City, Shandong province 250200 Huiquan Road Applicant before: Tian Jing |
|
| ASS | Succession or assignment of patent right |
Owner name: SU LEI Free format text: FORMER OWNER: TIAN JING Effective date: 20150619 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: TIAN JING ZHANG WEICONG TO: SU LEI |
|
| GR01 | Patent grant | ||
| C14 | Grant of patent or utility model | ||
| EXPY | Termination of patent right or utility model | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150729 Termination date: 20151101 |